SOR-C13 TFA, a carboxy-terminal truncated peptide, is a high-affinity TRPV6 antagonist with an IC 50 value of 14 nM. TRPV6 is a non-voltage gated calcium channel that is associated with malignancy and poor prognosis in breast cancer. SOR-C13 TFA has anticancer activity.
性状
Solid
IC50 & Target[1][2]
TRPV6 14 nM (IC50)
体内研究(In Vivo)
SOR-C13 (腹腔给药; 400, 600, 800 mg/kg; 每天; 第 1 至 12 天) TFA 可有效抑制雌性 NOD/SCID 小鼠 SKOV-3 细胞肿瘤的生长。 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: Female NOD/SCID mice with SKOV-3 cell
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Sealed storage, away from moisture and lightPowder -80°C 2 years;-20°C 1 year
[1]. S Fu , et al. Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2017 Jun;35(3):397. [2]. Hui Xue, et al. Inhibition of Transient Receptor Potential Vanilloid 6 channel, elevated in human ovarian cancers, reduces tumour growth in a xenograft model. J Cancer. 2018 Aug 6;9(17):3196-3207.
溶解度数据
In Vitro: H2O : 100 mg/mL (59.53 mM; Need ultrasonic)配制储备液